(Q58610296)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

3 references

14 November 2020

30 January 2021

9 October 2022

Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

14 November 2020

3 references

14 November 2020

30 January 2021

9 October 2022

pancreatic ductal carcinoma

3 references

14 November 2020

30 January 2021

9 October 2022

phosphoinositide-3 kinase inhibitor

1 reference

30 January 2021

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

David Herrmann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Jennifer P. Morton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

author name string

Tr Jeffry Evans

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Paul Timpson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

language of work or name

English

0 references

publication date

5 November 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 April 2019

3 references

14 November 2020

30 January 2021

9 October 2022

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

14 November 2020

30 January 2021

9 October 2022

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

page(s)

742-758

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

2 May 2020

copyright license

3 references

14 November 2020

30 January 2021

9 October 2022

0 references

Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha

1 reference

12 December 2020

Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness

1 reference

12 December 2020

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

1 reference

12 December 2020

Dual action of tirapazamine in the induction of DNA strand breaks

1 reference

12 December 2020

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

1 reference

12 December 2020

p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

1 reference

12 December 2020

Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression

1 reference

12 December 2020

Cancer risks in BRCA2 mutation carriers

1 reference

12 December 2020

Cancer statistics, 2000.

1 reference

12 December 2020

BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications

1 reference

12 December 2020

Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma

1 reference

12 December 2020

Progression model for pancreatic cancer.

1 reference

12 December 2020

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

1 reference

12 December 2020

HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation

1 reference

12 December 2020

PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy

1 reference

12 December 2020

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

1 reference

12 December 2020

Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

1 reference

12 December 2020

Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression

1 reference

12 December 2020

Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors

1 reference

12 December 2020

Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia

1 reference

12 December 2020

Pancreatic cancer biology and genetics

1 reference

12 December 2020

Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells

1 reference

12 December 2020

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

1 reference

12 December 2020

Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays

1 reference

12 December 2020

Incidence, mechanism and prognostic value of activated AKT in pancreas cancer

1 reference

12 December 2020

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

1 reference

12 December 2020

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

12 December 2020

Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion

1 reference

12 December 2020

The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.

1 reference

12 December 2020

Pancreatic Intraepithelial Neoplasia in Association With Intraductal Papillary Mucinous Neoplasms of the Pancreas

1 reference

12 December 2020

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

1 reference

12 December 2020

Precursors to invasive pancreatic cancer

1 reference

12 December 2020

Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration

1 reference

12 December 2020

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

12 December 2020

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

12 December 2020

Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance

1 reference

12 December 2020

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

1 reference

12 December 2020

Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT

1 reference

12 December 2020

International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas

1 reference

12 December 2020

Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition

1 reference

12 December 2020

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

12 December 2020

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

12 December 2020

Divorcing ARF and p53: an unsettled case

1 reference

12 December 2020

Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

1 reference

12 December 2020

Opposing Roles for Akt1 and Akt2 in Rac/Pak Signaling and Cell Migration

1 reference

12 December 2020

Cancer risks among BRCA1 and BRCA2 mutation carriers

1 reference

12 December 2020

A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma

1 reference

12 December 2020

Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

1 reference

12 December 2020

AKT/PKB signaling: navigating downstream

1 reference

12 December 2020

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

1 reference

12 December 2020

Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study

1 reference

12 December 2020

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

1 reference

12 December 2020

p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK.

1 reference

12 December 2020

The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity

1 reference

12 December 2020

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

1 reference

12 December 2020

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

1 reference

12 December 2020

Update on pancreatic intraepithelial neoplasia.

1 reference

12 December 2020

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.

1 reference

12 December 2020

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

1 reference

12 December 2020

Hypoxia, HIF1 and glucose metabolism in the solid tumour

1 reference

12 December 2020

KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin

1 reference

12 December 2020

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

12 December 2020

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

1 reference

12 December 2020

Margin clearance and outcome in resected pancreatic cancer

1 reference

12 December 2020

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

1 reference

12 December 2020

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival

1 reference

12 December 2020

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer

1 reference

12 December 2020

p53-Induced apoptosis and inhibitors of p53.

1 reference

12 December 2020

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

12 December 2020

Significance of mucin expression in pancreatobiliary neoplasms

1 reference

12 December 2020

Epidemiology of pancreatic cancer: an overview

1 reference

12 December 2020

THE METABOLISM OF TUMORS IN THE BODY

1 reference

12 December 2020

The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?

1 reference

12 December 2020

Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

1 reference

12 December 2020

Mutant p53 drives invasion by promoting integrin recycling

1 reference

12 December 2020

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3

1 reference

12 December 2020

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

1 reference

12 December 2020

mTOR signaling and drug development in cancer

1 reference

12 December 2020

Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy

1 reference

12 December 2020

1 reference

12 December 2020

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

1 reference

12 December 2020

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors

1 reference

12 December 2020

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

1 reference

12 December 2020

Pancreatic intraepithelial neoplasia – can we detect early pancreatic cancer?

1 reference

12 December 2020

Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

1 reference

12 December 2020

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer

1 reference

12 December 2020

A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).

1 reference

12 December 2020

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome

1 reference

12 December 2020

Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis.

1 reference

12 December 2020

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

1 reference

12 December 2020

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

12 December 2020

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

12 December 2020

Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer

1 reference

12 December 2020

Cystic precursors to invasive pancreatic cancer

1 reference

12 December 2020

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

1 reference

12 December 2020

PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

1 reference

12 December 2020

Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies

1 reference

12 December 2020

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

1 reference

12 December 2020

Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis

1 reference

12 December 2020

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

12 December 2020

Targeting hypoxia in cancer therapy

1 reference

12 December 2020

Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades

1 reference

12 December 2020

Multiple stress signals activate mutant p53 in vivo

1 reference

12 December 2020

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network

1 reference

12 December 2020

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

1 reference

12 December 2020

Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia

1 reference

12 December 2020

Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes.

1 reference

12 December 2020

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

1 reference

12 December 2020

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

1 reference

12 December 2020

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.

1 reference

12 December 2020

The translational landscape of mTOR signalling steers cancer initiation and metastasis

1 reference

12 December 2020

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

1 reference

12 December 2020

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

1 reference

12 December 2020

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.

1 reference

12 December 2020

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

1 reference

12 December 2020

Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma

1 reference

12 December 2020

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

1 reference

12 December 2020

Regulation and function of mTOR signalling in T cell fate decisions

1 reference

12 December 2020

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

1 reference

12 December 2020

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Overexpression of the B-type Eph and ephrin genes correlates with progression and pain in human pancreatic cancer

1 reference

12 December 2020

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

1 reference

12 December 2020

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

1 reference

12 December 2020

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

1 reference

12 December 2020

Keys to personalized care in pancreatic oncology

1 reference

12 December 2020

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

1 reference

12 December 2020

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

1 reference

12 December 2020

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.

1 reference

12 December 2020

Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs.

1 reference

12 December 2020

MDM2, MDMX and p53 in oncogenesis and cancer therapy

1 reference

12 December 2020

Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.

1 reference

12 December 2020

Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer

1 reference

12 December 2020

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

1 reference

12 December 2020

Outlier kinase expression by RNA sequencing as targets for precision therapy.

1 reference

12 December 2020

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

1 reference

12 December 2020

Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer

1 reference

12 December 2020

Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?

1 reference

12 December 2020

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

1 reference

12 December 2020

A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.

1 reference

12 December 2020

Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles

1 reference

12 December 2020

Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer

1 reference

12 December 2020

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.

1 reference

12 December 2020

Clinical and molecular characterization of HER2 amplified-pancreatic cancer.

1 reference

12 December 2020

Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma

1 reference

12 December 2020

The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma

1 reference

12 December 2020

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

1 reference

12 December 2020

Inferring tumour purity and stromal and immune cell admixture from expression data

1 reference

12 December 2020

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

12 December 2020

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia

1 reference

12 December 2020

Mutant KRAS is a druggable target for pancreatic cancer

1 reference

12 December 2020

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models

1 reference

12 December 2020

Therapeutic targeting of EPH receptors and their ligands

1 reference

12 December 2020

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

1 reference

12 December 2020

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas

1 reference

12 December 2020

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

1 reference

12 December 2020

Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion

1 reference

12 December 2020

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

1 reference

12 December 2020

Mutant p53 in cancer: new functions and therapeutic opportunities

1 reference

12 December 2020

Targeting mTOR dependency in pancreatic cancer

1 reference

12 December 2020

Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling

1 reference

12 December 2020

Developments in preclinical cancer imaging: innovating the discovery of therapeutics.

1 reference

12 December 2020

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

1 reference

12 December 2020

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

1 reference

12 December 2020

Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.

1 reference

12 December 2020

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

1 reference

12 December 2020

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

1 reference

12 December 2020

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

1 reference

12 December 2020

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma

1 reference

12 December 2020

PI3K/Akt-mediated regulation of p53 in cancer

1 reference

12 December 2020

Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas

1 reference

12 December 2020

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers

1 reference

12 December 2020

PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice

1 reference

12 December 2020

Drugging the undruggable RAS: Mission possible?

1 reference

12 December 2020

A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer

1 reference

12 December 2020

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

1 reference

12 December 2020

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

1 reference

12 December 2020

Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.

1 reference

12 December 2020

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

1 reference

12 December 2020

Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α

1 reference

12 December 2020

SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer

1 reference

12 December 2020

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

1 reference

12 December 2020

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

1 reference

12 December 2020

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

1 reference

12 December 2020

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

1 reference

12 December 2020

Whole genomes redefine the mutational landscape of pancreatic cancer

1 reference

12 December 2020

Surgical management of pancreatic cancer--pancreaticoduodenectomy

1 reference

12 December 2020

Surgical management of pancreatic cancer--distal pancreatectomy

1 reference

12 December 2020

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

1 reference

12 December 2020

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

1 reference

12 December 2020

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

1 reference

12 December 2020

Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance

1 reference

12 December 2020

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

1 reference

12 December 2020

Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

1 reference

12 December 2020

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

1 reference

12 December 2020

Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.

1 reference

12 December 2020

Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT

1 reference

12 December 2020

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial

1 reference

12 December 2020

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.

1 reference

12 December 2020

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

1 reference

12 December 2020

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

1 reference

12 December 2020

Drugging PI3K in cancer: refining targets and therapeutic strategies

1 reference

12 December 2020

Targeting cancer cell metabolism in pancreatic adenocarcinoma

1 reference

12 December 2020

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

1 reference

12 December 2020

Familial Pancreatic Adenocarcinoma

1 reference

12 December 2020

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

1 reference

12 December 2020

Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.

1 reference

12 December 2020

The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis

1 reference

12 December 2020

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models

1 reference

12 December 2020

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

1 reference

12 December 2020

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.

1 reference

12 December 2020

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors

1 reference

12 December 2020

Patient-centric trials for therapeutic development in precision oncology.

1 reference

12 December 2020

A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors

1 reference

12 December 2020

Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization

1 reference

12 December 2020

Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival

1 reference

12 December 2020

A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas

1 reference

12 December 2020

Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer

1 reference

12 December 2020

Genomic analyses identify molecular subtypes of pancreatic cancer

1 reference

12 December 2020

Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer.

1 reference

12 December 2020

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind

1 reference

12 December 2020

Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs.

1 reference

12 December 2020

GPCR Signaling Mediates Tumor Metastasis via PI3Kβ

1 reference

12 December 2020

Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer

1 reference

12 December 2020

Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors

1 reference

12 December 2020

Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression

1 reference

12 December 2020

Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents.

1 reference

12 December 2020

Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling

1 reference

12 December 2020

The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer

1 reference

12 December 2020

Pancreatic cancer biology and genetics from an evolutionary perspective

1 reference

12 December 2020

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

1 reference

12 December 2020

HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.

1 reference

12 December 2020

A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns

1 reference

12 December 2020

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

1 reference

12 December 2020

Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents

1 reference

12 December 2020

HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer

1 reference

12 December 2020

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

1 reference

12 December 2020

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.

1 reference

12 December 2020

Genetic disruption of the pHi-regulating proteins Na+/H+ exchanger 1 (SLC9A1) and carbonic anhydrase 9 severely reduces growth of colon cancer cells

1 reference

12 December 2020

Mitochondrial mutations and metabolic adaptation in pancreatic cancer.

1 reference

12 December 2020

A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis

1 reference

12 December 2020

Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell:cell repulsion

1 reference

12 December 2020

Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.

1 reference

12 December 2020

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.

1 reference

12 December 2020

A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway

1 reference

12 December 2020

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

1 reference

12 December 2020

TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α.

1 reference

12 December 2020

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

1 reference

12 December 2020

HER2-positive breast cancer is lost in translation: time for patient-centered research

1 reference

12 December 2020

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.

1 reference

12 December 2020

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors

1 reference

12 December 2020

Dynamic Rearrangement of Cell States Detected by Systematic Screening of Sequential Anticancer Treatments.

1 reference

12 December 2020

Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway

1 reference

12 December 2020

Survival of pancreatic cancer cells lacking KRAS function.

1 reference

12 December 2020

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

1 reference

12 December 2020

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer

1 reference

12 December 2020

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

1 reference

12 December 2020

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts.

1 reference

12 December 2020

Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer.

1 reference

12 December 2020

Cancer statistics, 2018.

1 reference

12 December 2020

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.

1 reference

12 December 2020

Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers.

1 reference

12 December 2020

Targeting the PI3K pathway in cancer: are we making headway?

1 reference

12 December 2020

Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.

1 reference

12 December 2020

Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice

1 reference

12 December 2020

Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice

1 reference

12 December 2020

Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells.

1 reference

12 December 2020

Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.

1 reference

12 December 2020

10.1136/GUTJNL-2018-316822

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30396902%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

PubMed publication ID

30396902

1 reference